Do you want to volunteer for Clinical Trials? Register now

Volunteer for Clinical Trials

Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.

Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.

Register now >

FDA approves new Hemophilia treatment

Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN® (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B. REBINYN® is the brand name for nonacog beta pegol, N9-GP. REBINYN® is indicated for on-demand treatment and control of bleeding episodes, […]

The post FDA approves new Hemophilia treatment appeared first on CenterWatch News Online.

Powered by WPeMatico

News

Pharmavize, Crystallics merge, launch Ardena

A new early phase contract development and manufacturing organization (CDMO), Ardena, has launched following the merging of Pharmavize and Crystallics.  The two companies came together in 2016 with backing from investor Mentha Capital. The new brand name, Ardena, reveals the increased service offering and complementary capabilities of Pharmavize in Belgium and Crystallics in the Netherlands. […]

more >

Alexion restructures, cuts workforce 20%

Alexion Pharmaceuticals announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected to deliver approximately $270 million in GAAP and approximately $250 million in non-GAAP pre-tax savings annually by 2019. The restructuring will reduce the company’s global workforce by approximately 20%. The resulting savings will allow Alexion […]

more >

ProQR spins out Amylon Therapeutics for CNS therapeutics

ProQR Therapeutics has spun out Amylon Therapeutics, a privately-held company focused on the development of therapies for central nervous system (CNS) disorders, with seed funding from a group of institutional and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop therapeutics for beta amyloid related disorders. Amylon […]

more >

James Ostell named National Center for Biotechnology Information director

National Library of Medicine (NLM) Director Patricia Flatley Brennan, R.N., Ph.D., has appointed James M. Ostell, Ph.D., as the director of the National Center for Biotechnology Information (NCBI), a division of NLM at the NIH. Dr. Ostell has been with NCBI since it was established by Congress in 1988, and has helped shape it into one […]

more >

Kyowa Hakko Kirin joins Certara’s Simcyp consortium

Certara, a provider of model-informed drug development and regulatory science, announced that Kyowa Hakko Kirin has joined the Simcyp Consortium and licensed the Simcyp Population-based Simulator. Kyowa Hakko Kirin is the 36th leading biopharmaceutical company and the 11th Japanese pharmaceutical company to join the Consortium. Member companies meet in a pre-competitive environment and work together to […]

more >

The CenterWatch Weekly, September 11, 2017

Novartis gets FDA approval for first-ever CAR-T cancer therapy; other applications on the horizon The emerging field of modifying and deploying a patient’s own cells to fight cancer just got some big legs under it with the late August approval of a new treatment for pediatric and young adult leukemia. The therapy, known as chimeric […]

more >